This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BIO-Europe Spring

€500 savings end in:

  • 00
    Days
  • 00
    Hrs
  • 00
    Mins
  • 00
    Secs
THE SPRINGTIME PARTNERING EVENT
March 18–20, 2024 | Barcelona, SpainMarch 26–27, 2024 | Digital Partnering

Newron Pharmaceuticals

Profile

Newron Pharmaceuticals S.p.A. is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system. Founded in 1999, Newron is committed to delivering innovative treatments to improve the quality of life for patients with CNS disorders. Our team has built a balanced and robust pipeline comprised of drug candidates at different clinical stages and has a proven track record of drug development and commercialization. Xadago® (safinamide) is the first New Chemical Entity approved in more than a decade for the treatment of Parkinson’s disease and is commercialized in the EU, the US and globally through Newron’s partners. In addition to Xadago® for Parkinson’s disease, Newron has a strong pipeline of promising treatments including Evenamide as the potential first add-on therapy for the treatment of patients with symptoms of schizophrenia and ralfinamide for patients with specific rare pain indications. Founded in 1999, Newron is headquartered in Bresso, near Milan, Italy, with a subsidiary in Morristown, NJ, USA. The Company is listed on the SIX Swiss Exchange, under the trading symbol NWRN, on the primary market of the Düsseldorf Stock Exchange and on XETRA, trading symbol NP5. Newron's corporate strategy comprises three pillars: 1. Leveraging its decades of CNS expertise — Including the development of Evenamide, a new concept in treating inadequate/non-response in schizophrenia 2. Maximizing Xadago’s market potential for Parkinson’s disease 3. In-licensing strategically relevant assets and partnering core assets